ATyr Pharma Inc. said it will be reducing its workforce by 30% following a decision to discontinue development of certain antibody candidates identified under its ORCA program for cancer.
The San Diego-based company will now advance ATYR1923 instead, which is being investigated as a treatment for a group of lung diseases.
The company said it was scrapping the development of the antibodies because they did not demonstrate sufficient efficacy to warrant further development.
The savings from these measures will also be utilized for additional research efforts under the ORCA program.
Antibodies are proteins that are used by the immune system to fight disease. Targeted antibody therapies are used to fight many forms of cancer.